Jublia (efinaconazole) Antifungal Cost, Side Effects, Results, And Effectiveness For Onychomycosis (Nail Fungus) | Brianne Chin, PharmD | RxEconsult
Menus

All Health Articles

Jublia (efinaconazole) Antifungal Cost, Side Effects, Prescribing Information for Onychomycosis Category: Fungal Infections by - June 19, 2014 | Views: 140738 | Likes: 0 | Comment: 0  

Jublia (efinaconazole) antifungal for onychomycosis

Brand Name: Jublia
Generic Name: efinaconazole 10% topical solution

Medication Class: Triazole Antifungal
Similar Drugs: None, Jublia is the first topical triazole antifungal agent
Manufactured by: Valeant Pharmaceuticals International, Inc.
FDA Approval Date: June 9, 2014

What is Jublia and its mechanism of action?                                            

Jublia is the first topical triazole antifungal agent developed for onychomycosis, a fungal infection of the nail (nail fungus). Onychomycosis is a common and destructive nail infection that occurs under the toenail or under the fingernail. Onychomycosis is a fungal infection caused by Trichophyton rubrum and Trichophyton mentagrophytes. Jublia works by blocking an enzyme that prevents the synthesis of ergosterol. Ergosterol is a chemical compound and an important part of fungal cell membranes. Fungi cannot survive without cell membranes. Jublia’s fungicidal action (fungi killing action) prevents the continued growth of fungi and heals the infection.

What does Jublia treat?

Jublia is FDA approved for the treatment of onychomycosis. Approximately 35 million people suffer from onychomycosis, the largest group affected are men between ages 50-70 years old.

The specific dermatophyte fungi that cause onychomycosis thrive in moist environments, such as swimming pools and showers and can invade the skin through cuts or separations between the toe and toenail. The infection starts as a small white or yellow spot underneath the nail and causes discoloration, thickening, or pain. If not treated, onychomycosis can cause permanent nail damage. There are around 85% of onychomycosis patients that are untreated.

Other treatments for onychomycosis include topical lacquers (e.g., ciclopirox), oral antifungal agents (e.g., terbinafine, itraconazole), and surgery.

What are interesting Jublia facts?

  • Jublia is the first topical triazole antifungal agent developed for onychomycosis.
  • Jublia is supplied in a specially designed bottle that uses an integrated flow-through brush applicator.
  • Jublia is detectable in breast milk of laboratory test rats. Nursing mothers should exercise caution. 
  • Jublia is flammable and patients should avoid pedicures, nail polish, or nail products when using Jublia.

Next: Warnings, Side Effects, Efficacy Results

Also Read: Hepatitis C Cure Rates And Treatment Guidelines For Direct-Acting Drug Treatments

 
 


For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2020 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap